Erratum: Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's disease (Cell Stem Cell (2024) 31(1) (25–38.e8), (S1934590923004010), (10.1016/j.stem.2023.11.009))

(Cell Stem Cell 31, 25–38.e1–e8; January 4, 2024) The authors wish to correct the errors that appeared in the originally published version of this article. These errors occurred inadvertently during the exchange and assembly of data by collaborators from four different institutes. The corrections that we have made do not affect the description of the results and conclusion of the study. In Figure 1B, we mistakenly included the same immunofluorescent images for FOXA2/LMX1A/B/DAPI at both DD19 and DD25. In Figure 2H, a few dots in the “Base” panel were mislabeled in incorrect colors: two red dots (one on the right and one on the left side) in the control group and two yellow dots (one on the right and one on the left side) in the cell transplanted group. In Figure 2I, we inadvertently used the same images for both the fourth week and eighth week for the vehicle-received and cell transplanted rats. To correct these errors, we have updated the affected panels and replaced Figure 1 and Figure 2 in our article online; a comparison of all affected panels also appears below. The authors sincerely apologize for any inconvenience caused by these errors.